We Need Your Advocacy to #SaveMedicaid

Federal Medicaid funding is on the chopping block, with potentially disastrous outcomes. Lend your voice today to ensure Congress does everything it can to protect Medicaid services.
Take Action Now
July 18, 2024
Partner Presentation

Epidiolex Case Study & Long-Term Care Outcomes

Share this page
In Partnership with
2:00pm-3:00pm EST

Epidiolex is the first and only FDA-approved cannabinoid designed specifically to address seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC).

Objectives

  • Describe basic seizure management in LTC settings that care for individuals with I/DD
  • Define characteristics of LGS in children and adults
  • Review the medication Epidiolex in terms of efficacy as well as the guidelines for management of potential side effects
  • Identify the BECOME study outcomes from a non-clinical perspective of potential changes in behavior, cognition, physical attributes, and emotional changes that can be seen secondary to the initiation of Epidiolex to treat seizures

Presenter

  • Nanette Wrobel, Director of Business Development, Tarrytown Expocare Pharmacy